myNEO ImmunoEngine

myNEO

myNEO ImmunoEngine

Personalised immunotherapy

Applications Immune System Diseases

Do you know anyone using myNEO ImmunoEngine?

The primary therapeutic focus of myNEO’s patient-specific tumour screening platform is personalised immunotherapy through neoantigen prediction. The ImmunoEngine enables determination of peptides uniquely presented on tumour cells of a patient which are then incorporated in a cancer vaccine, to stimulate the recognition of the tumour by the patient’s own immune system.

Over 40 % of people will get diagnosed with cancer and half of them will still succumb to it even after being treated. As such, cancer was responsible for an estimated 9.6 million deaths in 2018. These figures expose the increasing need for novel therapies that can eradicate cancer. One of the major problems is the variability inherent to cancers, even within the same clinical tumour subtype, as each tumour is characterised by its own set of alterations that have accumulated during differentiation.

Anti-tumour immunotherapy has gathered major attention in the search for innovative strategies to fight cancer. It merges the field of oncology with immunology into immuno-oncology, an exciting path that has the potential to dramatically improve treatment efficacy and specificity. Although generic immunotherapy (e.g. anti PD-1, PD-L1, CTLA-4) has delivered meaningful results in certain indications, 70 % of the patients do not respond to such a non-personalised form of immune stimulation. redirecting the immune system against a specific target on cancer cells ensures a strong, long-lived, and broad immune response leading to tumour regression.

A schematic illustration of how the immune system naturally recognises a tumour cell is portrayed below. Since tumour cells are genomically distinct from healthy cells, they also contain a different set of peptides presented onto their surface via MHC molecules. T-cells recognise these aberrant peptides upon binding them and subsequently induce cell death in the tumour. By identifying these unique tumour MHC-binding neoantigens, the immune response can be primed/boosted against these antigens, evoking immunological memory and prolonged protection against the specific malignancy.

Different types of cancer immunotherapy treatments manage to launch an attack against tumour-specific targets using the immune system. For example, during cancer vaccination, dendritic cells are educated to prime cytotoxic T-cells against these tumour-specific antigens to specifically recognise and eliminate tumour cells.

myNEO ImmunoEngine

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.


© 2023 Netspective Media LLC. All Rights Reserved.

Built on Feb 3, 2023 at 6:31am